Merck licenses Arvinas' protein degradation platform

Arvinas LLC (New Haven, Conn.) granted Merck & Co. Inc. (NYSE:MRK) an exclusive, multi-year license to use the biotech's proteolysis-targeting chimeric molecule (PROTAC) platform to develop therapeutics against undisclosed targets.

While Arvinas' internal pipeline is focused on oncology, Merck will seek to apply the PROTAC platform across multiple therapeutic areas. Arvinas declined to disclose details regarding disease targets and Merck did not respond to inquiries. ...